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Abstract
Background: Osteosarcoma is the most common primary bone malignancy in childhood and adolescence.
However, it is very rare in children under 5 years of age. Although studies in young children are limited in number,
they all underline the high rate of amputation in this population, with conflicting results being recently reported
regarding their prognosis.
Methods: To enhance knowledge on the clinical characteristics and prognosis of osteosarcoma in young children,
we reviewed the medical records and histology of all children diagnosed with osteosarcoma before the age of five
years and treated in SFCE (Société Française des Cancers et leucémies de l’Enfant) centers between 1980 and 2007.
Results: Fifteen patients from 7 centers were studied. Long bones were involved in 14 cases. Metastases were
present at diagnosis in 40% of cases. The histologic type was osteoblastic in 74% of cases. Two patients had a
relevant history. One child developed a second malignancy 13 years after osteosarcoma diagnosis.
Thirteen children received preoperative chemotherapy including high-dose methotrexate, but only 36% had a
good histologic response. Chemotherapy was well tolerated, apart from a case of severe late convulsive
encephalopathy in a one-year-old infant. Limb salvage surgery was performed in six cases, with frequent
mechanical and infectious complications and variable functional outcomes.
Complete remission was obtained in 12 children, six of whom relapsed. With a median follow-up of 5 years, six
patients were alive in remission, seven died of their disease (45%), in a broad range of 2 months to 8 years after
diagnosis, two were lost to follow-up.
Conclusions: Osteosarcoma seems to be more aggressive in children under five years of age, and surgical
management remains a challange.
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Background
Osteosarcoma mainly occurs in teenagers and young
adults. It is the most frequent primary bone malig-
nancy in children and adolescents under 24 years of
age, with an annual incidence of 4.4 cases per million
in the United States [1]. In France, the annual inci-
dence is 3.6 cases per million children under 15 years
of age [2] and 9.2 per million adolescents aged from
15 to 19 years [3]. These patients’ prognosis has
improved markedly over the last three decades, with
the use of multiagent chemotherapy and the frequency
of amputation decreased over time with the advance of
endoprosthesis technology and conservative surgery.
Several studies have attempted to assess the impact of
age on prognosis, comparing survival rates in children
u n d e rt h ea g e so f1 0 ,1 2o r1 4y e a r sw i t ht h o s e
obtained in older patients with current therapies [4-6].
In 2003, Nagarajan et al reported comparable out-
comes for children who presented with localised osteo-
sarcoma at the age of 10 years or less and for those
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only limited series and case reports have been
described in very young children [7-13]. Last year, sev-
eral groups reported studies focused specifically on
children under five years old. They represent only 1 to
2.8% of cases, but the rate of amputation remains high
in these children [14-16]. Regarding prognosis, con-
flicting results were reported: some authors finding
inferior outcomes compared to older children, even
using a Cox proportional hazards model controlling
for metastatic status [15], others finding that survival
was in the range of that observed for older patients
[14,16]. However, in the Italian series, patients with
metastases at diagnosis were excluded.
The aim of this retrospective study was to enhance
knowledge on the clinical characteristics of osteosar-
coma in children under 5 years of age and to elucidate
whether there is any difference with regards to the out-
come between very young and older patients. We speci-
fically investigated whether children who developed
osteosarcoma so early in their life had underlining con-
dition and could have a different tumour biology, how
many had disseminated disease at diagnosis and how
they responded to and tolerated chemotherapy. The
functional outcome of lower-limb surgery was also
examined as surgical management of these children
remains a challenge.
Methods
This study was approved by the DIUOP (pediatric
oncology inter university graduation, coordinated by G.
Vassal, MD, PhD) educational committee (including
scientific and ethic evaluation of all research projects).
We analysed the medical records of all children under
five years of age at diagnosis of osteosarcoma who were
treated in member centers of the Société Française de
lutte contre les Cancers et leucémies de l’Enfant et de
l’adolescent (SFCE) between 1980 and 2007.
The following information was collected: clinical char-
acteristics (age at diagnosi s ,s e x ,m e d i c a lb a c k g r o u n d
and genetic predisposition to cancer); tumour character-
istics (location, size, metastatic status at diagnosis);
treatment (preoperative chemotherapy, surgery, post-
operative treatment, adverse effects); and outcome
(remission, relapse, survival). Functional status was
obtained from the patients’ orthopaedists. The histologic
diagnoses were confirmed by centralized slide review.
Survival was calculated using the Kaplan-Meir method,
with standard errors [17]. Overall survival was calculated
from diagnosis until death and event free survival until
progression for patients who never achieved complete
remission, or relapse for those who had complete surgi-
cal resection of the tumour.
Results
Fifteen children (7 girls and 8 boys) under 5 years of age
were treated for osteosarcoma between January 1980
and December 2007 in 7 SFCE centers. They were aged
between 1.0 and 4.9 years (median 3.9 years).
Two patients had relevant histories:
- A 3-year-old girl had constitutional tall height
(105.5 cm at diagnosis, +4 SD), with no etiologic
diagnosis
- A 4.2-year-old boy had a polymalformative syn-
drome with intrauterine growth retardation, micro-
cephaly and blindness. He had received growth
hormone for three years before osteosarcoma onset.
Only one patient, a one-year-old boy, had molecular
studies, which showed normal Rb and P53 gene status.
None of the patients had a family history of cancer.
Clinical features are described in table 1. Pain was the
most frequent presenting symptom (n = 12). Swelling
was prominent in two cases, and one pathological frac-
ture occurred after a mistaken treatment for a bone
cyst. The median duration of symptoms before diagnosis
was 53 days (15-180 days) overall, and respectively 56
and 60 days in patients with metastatic and localized
forms. The primary tumour was located on a long bone
in 14 cases (femur, n = 11, 73%; tibia, n = 1; humerus, n
= 2). The tumour involved the whole bone in 2 cases.
The diaphysis was involved alone in 4 cases, and the
epiphysis in 8 cases. One tumour affected a rib. In the
14 patients with long-bone primary tumours, the med-
ian dimensions were 54 mm (28-106 mm) by 36.4 mm
(10-50 mm). Six patients (40%) had pulmonary metasta-
sis at diagnosis. None of the patients had metastasis of
bone or other tissues at diagnosis.
Centralized slide review showed that 12 tumours were
conventional osteoblastic osteosarcomas, while one was
mixed (osteoblastic, chondroblastic and fibroblastic),
one was telangiectasic, and one was fibroblastic.
Treatments are summarized in table 2. Thirteen chil-
dren received preoperative chemotherapy. Nine patients
received previously described regimens, consisting of the
Rosen T10 protocol in 1 case [18], HELP in 2 cases
[19], Os 87 in 2 cases [20], and Os 94 in 4 cases [21].
Two patients received the French Os 2005 regimen pre-
operatively, consisting of seven courses of high-dose
methotrexate (HDMTX: 12 g/m
2) with leucovorin res-
cue and two courses of etoposide (300 mg/m
2) and ifos-
famide (12 g/m
2). Patients with good response to
chemotherapy received 12 courses of HDMTX and 3
courses of etoposide and ifosfamide post-operatively,
while patients with poor response to chemotherapy
received 10 courses of HDMTX and 5 courses of
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2) plus doxorubicin (75 mg/
m
2). One patient received HDMTX and vincristine
before surgery, and one patient received HDMTX and
doxorubicine. Two patients received no preoperative
treatment.
The tumour progressed in 5 cases during pre-opera-
tive treatment, which was halted. Surgery was
conservative in 6 (40%) of these 13 children who
received preoperative chemotherapy, while six patients
were amputated and one was lost to follow-up when the
tumour progressed. Conservative surgery consisted in
resection and reconstruction by: prosthesis in 2 cases,
expanding endoprosthesis in one case, vascularised
fibula in 2 cases, and other type of autologous bone
Table 1 Patients characteristics at diagnosis
Patient Year range of diagnosis Age range at diagnosis (years) Duration range of symptoms (months) Metastases at diagnosis
1 2-3 NA yes
2 3-4 <2 yes
3 1980 -1989 3-4 <2 no
4 3-4 <2 no
5 4-5 >4 no
6 4-5 2-4 yes
7 4-5 <2 no
8 1990 -1999 4-5 2-4 no
9 3-4 <2 no
10 4-5 <2 yes
11 3-4 2-4 no
12 2000 -2007 4-5 <2 yes
13 1-2 <2 no
14 4-5 <2 no
15 2-3 2-4 yes
NA: data non-available
Table 2 treatment and evolution of patients
Patient Preoperative
chemotherapy
Surgery % Viable tumor
cells
Post operative chemotherapy Relapse Status
1 no desarticulation of the
hip
NAp no NAp dod
2 HD MTX, VCR amputation NA CDDP NAp dod
3 T10 desarticulation 100% DOX, CDDP, bleo, actinomycin,
cyclo
lung dod
4 os 87 resection-
reconstruction
30% Ifosfamide, vindesine local Lost to follow-up
5 HD MTX, DOX resection-
reconstruction
10% DOX, HD MTX no CR1
6 HELP tigh’s amputation 3% HELP bone dod
7 os 87 amputation 60% os87 lung dod
8 HELP Trans-iliac amputation 8% HELP no CR1 second
cancer
9 os 94 resection-prothesis 80% VP16, ifosfamide lung dod
10 os 94 amputation >50% os 94 local dod
11 os 94 resection-
reconstruction
15% os 94 no CR1
12 os 94 resection-prothesis 0% os 94 no CR1
13 no costectomy NAp os 94 no CR1
14 os 05 resection-prothesis 8% os 05 no CR1
15 os 05 NA NA NA NA Lost to follow-up
dod: Dead of disease, CR1: first complete remission, NA: data non available, Nap: data non applicable, VCR: vincristine, DOX: doxorubicine, HDMTX: High dose
Methotrexate, CDDP: cisplatin, bleo: bleomycin, cyclo: cyclophosphamide.
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local surgery, 13 of them had microscopic complete
tumour resection and for the patient remaining, quality
of resection was not available. The histologic response
was available in 11 cases. Only 4 patients (36%) had a
good histologic response to chemotherapy, with less
than 10% of viable tumour cells. Two of these patients
had Huvos grade III or IV responses [18].
Post-operative chemotherapy is summarized in table 2.
Chemotherapy was complicated by two cases of septi-
caemia, one electrolyte disorder, and one case of grade
III hepatic toxicity.
Overall and event free survival curves of the whole
g r o u po fp a t i e n t sa r es h o w ni nF i g u r e1 .T h eo v e r a l l
survival rate at 5 years was 55% (95% confidence interval
30-78%), the event-free survival was 47% (95% confi-
dence interval 23-70%). Out of 15 patients, 12 achieved
a complete remission, but 6 of them had recurrences, in
lung (n = 3) or bone (n = 3). One child was successfully
treated for renal adenocarcinoma, which occurred 14
years after osteosarcoma diagnosis. With a median fol-
low-up of 5 years, six patients were alive in first com-
plete remission with no evidence of disease. Two
patients were lost to follow-up with progressive disease,
and 7 died of their disease. The median time between
diagnosis and death was 12 months (range 2 months to
8 years).
We also examined functional outcome in the 9 chil-
dren who survived for more than one year after diagno-
sis. One child had ablation of a rib, with no mechanical
or pulmonary complications 3 years after diagnosis. One
patient had a good functional result after tumour resec-
tion of the upper third of the humerus, reconstructed
with a cement spacer. Three children had lower-limb-
sparing surgery with reconstruction by vascularised
fibula (2 cases) and growth’s prosthesis (1 case). They
were re-operated on between one and five times, for
infections, prosthesis fracture, pseudoarthrosis, unequal
limb length or varisation. One patient had a good func-
tional result eight years after the first operation, the sec-
ond patient still needed an orthesis for walking 5 years
l a t e r ,a n dt h et h i r dp a t i e n th a dv e r yp o o rk n e e - j o i n t
function and a length discrepancy of 5.5 cm. Among the
four amputated children, two had transiliac or inter-ilio-
abdominal amputation with acceptable functional results
after prosthetic rehabilitation 6 months to 1 year after
surgery. One boy had thigh amputation and was unable
to receive prosthetic rehabilitation, owing to mental
retardation. The other patient with thigh amputation
was able to walk unassisted with prosthesis.
2 2 3 4 4 4 5 8 8 11 15












Figure 1 Overall (———) and event-free (- - -) survival of the whole group of patients. Vertical bars denote 95% confidence intervals at 5
years.
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and auditory function remained normal in all the chil-
dren who received doxorubicin or CDDP. Nevertheless,
the youngest child, a one-year-old infant, suffered severe
neurologic toxicity. He first developed severe peripheral
neuropathy (despite not receiving vincristine or cispla-
tin) five months after ifosfamide administration. He then
developed severe late convulsive encephalopathy two
years after the end of chemotherapy, with white sub-
stance signal abnormalities on MRI, possibly attributable
to HDMTX.
Discussion
Osteosarcoma is exceedingly rare in young children. In
France, Desandes et al found an incidence of 9.2 cases
per million adolescents [3], compared to only 0.4 per
million under-fives [2]. In our small series of 15 patients
the sex ratio was 1.1 in favor of males, compared to 2.1
in adolescents in France [3]. The tumour arose in the
diaphysis in 6 cases, compared to only 4% of cases in
Pakos’ series of 2680 patients [22].
Factors predisposing to cancer are a question of inter-
est in patient developing an osteosarcoma at young age.
No genetic predisposition was found in our population,
but germinal mutation of Rb and p53 have only been
investigated in one child. Another 3-year-old child had
constitutional tall height (+4 SD). Osteosarcoma usually
occurs during periods of rapid growth, but the relation-
ship with height remains controversial, recent retrospec-
tive studies having given contradictory results. Buckley
found no consistent relation with height in a case-con-
trol study of 152 children with osteosarcoma [23], while
Gelberg found a significant positive association with
height one year before diagnosis [24]. Adult patients
with acromegaly have been reported to be subject to
osteosarcoma [25]. In our series, one child was treated
with growth hormone (GH) for 3 years before diagnosis,
following intrauterine growth retardation and a polymal-
formative syndrome, without biological GH deficiency.
Due to this syndrome, a genetic predisposition to
tumour cannot be excluded. However isolated cases of
osteosarcoma have been reported during GH treatment,
but no formal relationship has been established [26,27].
Carel et al reported that GH-treated children had a rela-
tive risk of 13.8 for bone cancer [28]. The benefit of GH
treatment probably outweighs the risks, but the indica-
tion should be examined closely in case of personal or
familial risk factors.
The average interval between symptom onset and
diagnosis was 2 months in our patients, in keeping with
other studies [13,29], but longer than in Kager et al
report [16]. Two children had mistakenly been treated
for benign tumours, by infiltration or resection.
Although benign tumours are more frequent than
neoplasms in young children [30], the possibility of
malignancy must be kept in mind.
Metastasis was found at diagnosis in 40% of the chil-
dren in this study, a rate higher than reported in older
children (10 to 20%) [31], or in young children by other
groups [15,16].
T h eo s t e o b l a s t i ch i s t o l o g i ct y p ep r e d o m i n a t e di no u r
series (73%), as in older patients and in the recent ger-
man study in young children [16]. Other studies found
fibroblastic type [14] or telangiectasic type [15] as pre-
dominant subtype. However, in those studies, centra-
lized slide review was not performed.
As this study spans a lengthy period, treatment was
heterogeneous. However, all the children who received
chemotherapy (14 out of 15) were treated with drugs
known to be effective in osteosarcoma (HDMTX, ifosfa-
mide, cisplatin or doxorubicin). A good tumour
response to pre-operative chemotherapy was obtained in
only 36% of our patients, while similar regimens have
been reported to give good responses in 56% to 64% of
patients with non-metastatic osteosarcoma [19,21,32]
and in 42% of patients with metastatic forms [29]. This
would suggest that preoperative chemotherapy is less
effective in younger children. Likewise, Cho [33]
reported good responses in only 2 (20%) of 10 children
under 7 years of age. These results, together with the
high frequency of metastases at diagnosis promote the
hypothesis of a different tumour biology in young chil-
dren, with more aggressive disease. An other explana-
tion could be differences in chemotherapy metabolism
in young patients. It has been demonstrated that sys-
temic methotrexare and doxorubicin clearance tended
to be lower in very young children [34], and quite
recently, Crews et al found that in children and young
adults with osteosarcoma, a lower methotrexate clear-
ance was associated with lower probability of survival
[35]. However recent studies did not find any difference
in histological response in young patients compared to
older patients [14,16] and previous methotrexate phar-
macokinetics analyses stated that high peak level were
associated with better outcome [36].
No major acute adverse effects of chemotherapy were
noted, but a one-year-old boy developed late neurotoxi-
city. His peripheral neuropathy was attributable to ifos-
famide, which is known to provoke painful peripheral
sensory neuropathy [37], while his late convulsive ence-
phalopathy and mental regression were attributable to
HDMTX. Severe leukoencephalopathy has been
described with this drug and cannot be avoided by foli-
nic acid supplementation [37].
As reported by others in young children, we found a
high amputation rate in our study, explained by tumour
progression in some cases (n = 5), but also by the com-
plexity of surgical reconstruction in young patients, and
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amputation appears to be decreasing over time: it was
51% in a French study in 1988 [38] and only 6% in the
Os 94 trial [21].
Owing to the small number of patients and the lack of
quality-of-life assessment, the functional outcome of
children who had lower-limb surgery was difficult to
assess. The 3 children who had limb-sparing surgery
had a high rate of mechanical complications. Skeletal
maturity is an important determinant of functional out-
come in children with greater growth potential. Limb-
sparing procedures are more problematic than in adults,
and remain a challenge in very young children
[13-16,32,39].
The overall and event-free survival rates in this study
are difficult to interpret, given the small number of
patients, but our results seem similar to those reported
by Kager et al [16]. It is noteworthy that 7 children (45%)
died of their disease. Currently, the reported survival rate
among children treated for osteosarcoma is about 19%
for metastatic patients [29] and 76% at 5 years for non
metastatic patients [21]. In Germany, Bielack et al
reported an overall survival rate of 65% at 5 years [32]. In
the US study by Mirabello et al, the overall survival rate
was 61% at 5 years between 1973 and 2004 among
patients under 24 years of age [1]. In very young children,
some authors did not find difference in survival com-
pared to older patients [12-14,16]. However, in a regis-
tries based study, Worch et al reported that in non
metastatic patients, 5-year overall survival estimate was
51.9% for children who were 5 years of age or younger at
diagnosis versus 67.3% for patients ages 6-19 years [15].
Metastasis at diagnosis is a well-known factor of poor
prognosis. In our series only 3 out of 6 metastatic
patients were alive at the cut-off date for this analysis.
The response to neoadjuvant chemotherapy was also
found to have a prognostic influence in most studies. In
our study, 1 of the 4 patients who had a good response
died, compared to 4 of the 7 patients with a poor
response. Kager et al also found a negative impact of
poor histological response on survival [16]. Six (50%) of
the 12 children who obtained full remission in our series
relapsed. This is a higher rate than in the Hartford’ss e r -
ies of young children treated in the United States (25%)
[13], but the same observation was done in Kager’s study,
who reported 11 recurrences among 23 patients (48%)
who achieved complete remission [16]. Our results con-
firm that pattern of recurrence seems to be similar to
older children with lung and bone involvement.
Conclusion
Despite the small number of patients in this series, our
findings provide further information on the characteris-
tics of osteosarcoma in children under 5 years of age. In
particular, this tumour frequently arises in the diaphysis
of long bones, and seems to be more aggressive than in
older patients, with a high frequency of metastasis at
diagnosis and a poor response to chemotherapy, leading
to poor survival. Given the growth potential in this age
range, it is crucial to carefully consider local treatment
options and their likely functional outcome.
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